Filing Flows › ClearPoint Neuro (CLPT) › Q3 2026 › vs Q3 2025
ClearPoint Neuro (CLPT) Q3 2026 vs Q3 2025 (year over year)
ClearPoint Neuro's revenue rose $3.2M (+36%) from $8.9M in Q3 2025 to $12.1M in Q3 2026. The biggest changes: Product +$1.3M (+19%); Capital Equipment and Software +$705K (+68%); Capital Equipment and Software Systems and Software Products +$621K (+96%).
ClearPoint Neuro, Q3 2026: revenue $12.1M (+36% year over year), operating margin -52.4%, net loss $7.5M, operating cash flow −$5.1M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Service | $4.2M | $3.5M | $684K | +20% |
| Biologics and Drug Delivery Services and License Fees | $3.7M | $3.1M | $600K | +19% |
| Product | $7.9M | $6.6M | $1.3M | +19% |
| Capital Equipment and Software | $1.7M | $1.0M | $705K | +68% |
| Capital Equipment and Software Systems and Software Products | $1.3M | $647K | $621K | +96% |
| Biologics and Drug Delivery Disposable Products | $1.2M | $1.3M | −$107K | -8% |
| Revenue | $12.1M | $8.9M | $3.2M | +36% |
| Income tax benefit | $4K | −$8K | $12K | — |
| Net loss | $7.5M | $5.9M | $1.6M | +27% |
| Costs & expenses | $19.5M | $14.8M | $4.8M | +32% |
| Operating costs | $18.4M | $14.1M | $4.3M | +30% |
| Interest & other, net | $1.1M | $607K | $525K | +86% |
| Cost of revenue | $5.0M | $3.3M | $1.8M | +54% |
| Research & development | $4.0M | $3.5M | $566K | +16% |
| SG&A | $3.8M | $3.6M | $255K | +7% |
| Other operating costs | $5.5M | $3.8M | $1.7M | +44% |
| Operating cash sources | $7.5M | $5.9M | $1.6M | +27% |
| Depreciation & amortization | $103K | $66K | $37K | +56% |
| Share-based compensation | $1.9M | $2.0M | −$142K | -7% |
| Working capital & other | $365K | $682K | −$317K | -46% |
| Cash used in operations | $5.1M | $3.1M | $2.0M | +64% |
| Net loss absorbed | $7.5M | $5.9M | $1.6M | +27% |
Questions
How much did ClearPoint Neuro's revenue grow year over year in Q3 2026?
ClearPoint Neuro's revenue rose $3.2M (+36%) from $8.9M in Q3 2025 to $12.1M in Q3 2026.
What drove ClearPoint Neuro's revenue change in Q3 2026?
Product +$1.3M (+19%); Capital Equipment and Software +$705K (+68%); Capital Equipment and Software Systems and Software Products +$621K (+96%).